AF
CABA icon

Avanza Fonder’s Cabaletta Bio CABA Stock Holding History

Avanza Fonder’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,605
Closed -$21.8K – 444
2025
Q1 		$21.8K Hold
17,605
– – ﹤0.01% 460
2024
Q4 		$40K Buy
+17,605
New +$61.8K ﹤0.01% 437

Other funds holding CABA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Avanza Fonder's CABA Position: Q2 2025 in Review

Avanza Fonder sold out of Cabaletta Bio (CABA) in Q2 2025, closing a stake of 17,605 shares — an estimated $21.8K sold.

Avanza Fonder first reported a position in CABA in Q4 2024 and held it in 2 quarters. The position peaked at $40K in Q4 2024. 86 funds tracked by Wall St. Rank hold CABA as of Q2 2025.

  • Avanza Fonder reported no remaining Cabaletta Bio position as of Q2 2025 after selling out during the quarter.
  • Avanza Fonder sold 17,605 Cabaletta Bio shares in Q2 2025, an estimated $21.8K.
  • Avanza Fonder first reported a position in Cabaletta Bio in Q4 2024 and held it in 2 quarters.
  • Avanza Fonder's Cabaletta Bio position peaked at $40K in Q4 2024.
  • 86 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2025.

Based on Avanza Fonder's 13F filing for Q2 2025, filed 14 Jul 2025.